Zymeworks Inc. (ZYME) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Zymeworks Inc. (ZYME) closed at USD 24.77 on 2026-10-14, a change of +28.3 % over the past year, with a market capitalization of USD 1.85B.

Zymeworks Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Zymeworks Inc. key figures

Previous close

USD 24.77 (2026-10-14)

1-year change

+28.3 %

Market cap

USD 1.85B

Enterprise value

USD 1.57B

P/E ratio (trailing)

-12.44

P/E ratio (forward)

24.37

EPS (trailing)

-2.07

EPS (forward)

1.06

PEG ratio

n/a

Price to book

22.89

Revenue growth

-90.6 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.62

Employees

231

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Zymeworks Inc.

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Zymeworks Inc. and compare it with other stocks.